BiotechTube
Home/NewAmsterdam Pharma Company/Professor Dr. John J.P. Kastelein
PD

Professor Dr. John J.P. Kastelein

Co-founder and Chief Scientific Officer

NewAmsterdam Pharma Company

Therapeutic Areas

Cardiovascular DiseaseMetabolic DiseaseDyslipidemiaAlzheimer's Disease

NewAmsterdam Pharma Company Pipeline

DrugIndicationPhase
Obicetrapib (TA-8995)Hypercholesterolemia / HeFH / ASCVDPhase 3
Obicetrapib + Ezetimibe FDCHypercholesterolemiaPhase 3

Leadership Team at NewAmsterdam Pharma Company

DM
Dr. Michael Davidson
Co-founding Chief Executive Officer
BJ
B.J. Jones
Chief Commercial Officer
EF
Eduardo Fornari
Chief Financial Officer
CB
Christie Ballantyne, M.D.
Chief of Cardiology (Baylor), Scientific Advisor
View full NewAmsterdam Pharma Company profile